BiotechTube

Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidemia

Conditions

Candidemia, Candidiasis, Invasive

Trial Timeline

Dec 11, 2024 → Jan 30, 2028

NCT ID
NCT05421858

About Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo

Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo is a phase 3 stage product being developed by Basilea Pharmaceutica for Candidemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05421858. Target conditions include Candidemia, Candidiasis, Invasive.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05421858Phase 3Recruiting

Competing Products

9 competing products in Candidemia

See all competitors
ProductCompanyStageHype Score
micafungin + Micafungin + CaspofunginAstellas PharmaApproved
85
MicafunginAstellas PharmaApproved
85
AmBisomeGilead SciencesApproved
84
Anidulafungin/FluconazolePfizerPhase 3
76
Anidulafungin + VoriconazolePfizerApproved
84
Anidulafungin + FluconazolePfizerPhase 3
76
AnidulafunginPfizerPhase 3
76
APX001Basilea PharmaceuticaPhase 2
47
APX001Basilea PharmaceuticaPhase 2
47

Other Products from Basilea Pharmaceutica

alitretinoinPhase 3
72
ceftobiprole medocaril + vancomycin+aztreonamPhase 3
72
alitretinoinPhase 3
72
ceftobiprole medocaril + Vancomycin plus CeftazidimePhase 3
72
ceftobiprole plus placebo + linezolid plus ceftazidimePhase 3
72